|
Colorectal Carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
While HER2/neu receptor tyrosine kinase is involved in various malignancies, studies on colorectal adenocarcinoma (CRC) remain controversial.
|
15753987 |
2005 |
|
Adenocarcinoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
While HER2/neu receptor tyrosine kinase is involved in various malignancies, studies on colorectal adenocarcinoma (CRC) remain controversial.
|
15753987 |
2005 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While HER2/neu receptor tyrosine kinase is involved in various malignancies, studies on colorectal adenocarcinoma (CRC) remain controversial.
|
15753987 |
2005 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While further validation and study are needed, preliminary results show that the HER2/neu gene amplification status of breast carcinomas can reliably be determined on thrombin and formalin cell block material by using ISH.
|
24678687 |
2014 |
|
Secondary malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
When crossed with mice expressing activated forms of the Neu receptor tyrosine kinase that selectively couple to the Grb2 or Shc signaling pathways the activated type I receptor increased the latency of mammary tumor formation but also enhanced the frequency of extravascular lung metastasis.
|
12808151 |
2003 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We then evaluated for correlations between CAV1, CAV2 and HER2/neu gene expression and clinicopathologic factors in the 162 breast cancer cases.
|
15305200 |
2004 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We then evaluated for correlations between CAV1, CAV2 and HER2/neu gene expression and clinicopathologic factors in the 162 breast cancer cases.
|
15305200 |
2004 |
|
Mammary Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
We studied effects on differentiation and cell death of erbB-2/neu during mammary-gland development in transgenic mice expressing an activated, oncogenic rat erbB-2/neu gene controlled by the mammary-gland-specific promoter from mouse-mammary-tumor virus (MMTV-LTR).
|
10699933 |
2000 |
|
Cholangiocarcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively reviewed cases of advanced gallbladder cancer and cholangiocarcinoma with HER2/neu genetic aberrations or protein overexpression who received HER2/neu-directed therapy between 2007 and 2014.
|
26022204 |
2015 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a case of an exceptional responder to molecular-targeted therapy for metastatic oropharyngeal squamous cell carcinoma using a chemotherapeutic agent FDA approved for breast cancer and targeting the HER2/Neu receptor in order to discuss the larger clinical implications.
|
28061634 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a case of an exceptional responder to molecular-targeted therapy for metastatic oropharyngeal squamous cell carcinoma using a chemotherapeutic agent FDA approved for breast cancer and targeting the HER2/Neu receptor in order to discuss the larger clinical implications.
|
28061634 |
2017 |
|
Metastatic Squamous Cell Carcinoma of the Oropharynx
|
0.010 |
Biomarker
|
disease |
BEFREE |
We present a case of an exceptional responder to molecular-targeted therapy for metastatic oropharyngeal squamous cell carcinoma using a chemotherapeutic agent FDA approved for breast cancer and targeting the HER2/Neu receptor in order to discuss the larger clinical implications.
|
28061634 |
2017 |
|
Endometrial adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have found that the c-erbB2/NEU transcripts are present in the Ishikawa endometrial cell line as well as in human endometrial adenocarcinoma cells.
|
9307054 |
1997 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
We have examined the potential role of neu receptor proto-oncogene in human pituitary tumorigenesis.
|
9231056 |
1997 |
|
Invasive Carcinoma
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
We examined tissue microarrays (TMAs) constructed from 814 formaldehyde-fixed paraffin-embedded archival specimens of cervical intraepithelial neoplasia (CIN)1 (n = 262), CIN2 (n = 230), CIN3 (n = 186) and invasive carcinoma (n = 136), for HER2/neu protein expression by immunohistochemistry (IHC) and for HER2/neu gene amplification by chromogenic in situ hybridization (CISH).
|
19775342 |
2009 |
|
Mammary Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We examined 86 primary formalin-fixed, paraffin-embedded breast tumors for overexpression of EGFR and NEU and correlated our findings with the presence of cell surface phosphotyrosine as an indicator of tyrosine kinase activity at the plasma membrane.
|
8931669 |
1996 |
|
Carcinoma, Ovarian Epithelial
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH).
|
18182111 |
2008 |
|
Epithelial ovarian cancer
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH).
|
18182111 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH).
|
18182111 |
2008 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that miR-183 is dysregulated in breast cancer and expression correlates with estrogen receptor and HER2/neu receptor expression.
|
20858276 |
2010 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that miR-183 is dysregulated in breast cancer and expression correlates with estrogen receptor and HER2/neu receptor expression.
|
20858276 |
2010 |
|
Metastatic malignant neoplasm to brain
|
0.010 |
Biomarker
|
disease |
BEFREE |
We compared the estrogen- (ER), progesterone- (PgR) and HER2/neu receptor status of the primary tumor with brain metastases in a series of 24 consecutive breast cancer patients.
|
28870906 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared the estrogen- (ER), progesterone- (PgR) and HER2/neu receptor status of the primary tumor with brain metastases in a series of 24 consecutive breast cancer patients.
|
28870906 |
2017 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We analyzed data on 526 Japanese adult women with breast cancer with respect to the relationship between the status of HER2/neu receptor expression and the recurrent state and survival from detection of the first recurrence.
|
11821814 |
2002 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We analyzed data on 526 Japanese adult women with breast cancer with respect to the relationship between the status of HER2/neu receptor expression and the recurrent state and survival from detection of the first recurrence.
|
11821814 |
2002 |